Switching from a Toxicity-Causing Antiretroviral to Enfuvirtide in Patients with HIV: The SWITCH TOX Study

Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), Matthias Stoll(Medizinische Hochschule Hannover), Sorin Rugină, Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Schlomo Staszewski(National Institute of Allergy and Infectious Diseases), Lucy Rowell(Roche (United Kingdom)), Markus Müller, Wulf O. Böcher(Boehringer Ingelheim (Germany)), Miklos Salgo(La Roche College), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Piotr Pulik
HIV Clinical Trials
December 1, 2008
10.1310/hct0906-375
Cited by 3

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2017|449
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
|Infection|2020|246
Chronic renal failure among HIV-1-infected patients
|AIDS|2007|231